upmc   PITTSBURGH CYTOGENETICS LABORATORY

 

LABORATORY SERVICES

 

Microarray tEsting

Select a tabbed option below to learn more:

  • Microarray Testing for Hematologic Disorders
  • Microarray Testing for Plasma Cell Neoplasms

MICROARRAY TESTING FOR HEMATOLOGIC DISORDERS

Click to expand

Microarray testing is available using a custom designed chip (KANCERRAY) for research purpose

PLATFORM FOR ONCOLOGY aCGH

We use the Agilent 180K custom designed oligonucleotide array platform, which was specifically designed and validated by Pittsburgh Cytogenetics Laboratory for the sole purpose of identifying acquired genomic alterations, DNA copy number gains and losses, associated with hematological cancers, such as CLL, CML, AML, T-cell and B-cell ALL. The 180,000 oligonucleotides on the KANCERRAY cover 900 genes involved in carcinogenesis and 78 cancer syndromes with a maximum probe spacing of one probe for every 25 Kb throughout the genome and one probe for every 1 Kb in clinical regions. (PMID: 26299921; PMID: 28214896).

CANCER RELATED GENES and CANCER SYNDROMES COVERED BY PCL KANCERRAY.

Click to zoom
chromothripsis

 

CLINICAL INDICATION FOR MICROARRAY ANALYSIS

  • Samples with normal Karyotype
  • Samples with poor chromosomal morphology
  • Samples with in vitro growth failure

ONCOLOGY STUDY REQUISITION FORM (PDF TABLE)

SPECIMENS FOR ONCOLOGY ARRAY TEST

  • Bone marrow aspirate
  • Oncology blood

 

 

SPECIMEN REQUIREMENT

ONCOLOGY (KARYOTYPING, FISH AND CGH)
Specimen Types Requirements Turnaround times
Bone marrow or Blood 3cc of Bone marrow or peripheral blood in a sodium heparin tube (green top)

Do not use lithium heparin tubes
 

 

SPECIMEN REQUIREMENTS (PDF TABLE)

ADVANTAGES FOR ONCOLOGY MICROARRAY ANALYSIS

  • No in vitro cell culture is needed for microarray analysis.
  • Microarray testing can provide copy number gain and loss when the conventional cytogenetics analysis is failure due to poor growth.
  • Microarray testing can detect copy number imbalances in the resolution of 150Kb.
  • Microarray testing can rapidly detect and characterize numerical chromosomal abnormalities and LOH in one experiment.
  • Microarray testing has high sensitivity and specificity.

LIMITATIONS FOR ONCOLOGY MICROARRAY ANALYSIS

  • Array CGH will not detect balanced translocations, polyploidy or inversions
  • Array CGH will not detect low level mosaicism (<20%).

Download PDF

MICROARRAY TESTING FOR plasma Cell neoplasms

Microarray on CD138+ Plasma Cell +IGH FISH

The microarray analysis performed on DNA from CD138 positive plasma cells provides additional knowledge regarding chromosomal alterations helping in disease classification, risk stratification, and treatment selection. In contrast to the FISH panel, microarray is high-throughput, highly accurate and superb new tool for evaluating of cancer genomes. FISH testing for 14q32.3 (IGH) rearrangement will be automatically performed with microarray. This microarray test replaces the former FISH panel.

When ordering, please indicate a suspected or previously diagnosed plasma cell myeloma. This information is crucial for an optimal separation of CD138+ cells, which can be successfully accomplished within 72 hours upon a bone marrow sample collection.

Please see laboratory approaches for Testing of patients with Plasma Cell Myeloma at the diagnosis, relapse and remission stages.

Microarray profile in patients with plasma cell myelom

Sample type:

CD138+ purified plasma cells isolated from a bone marrow sample,  10-20 cells are sufficient for microarray analysis

Indications:

Suspected or definite diagnosis of Plasma Cell Myeloma, MGUS, Plasma Cell Leukemia

Regions tested:

Unbalanced alterations of all chromosomes

Advantages:

Requires very few plasma cells in a sample
Detection of additional genomic alterations of prognostic and diagnostic significance

Limitations:  

Balanced rearrangements involving IGH will require concurrent FISH studies

FISH studies:

Complementary IGH/CCND1, IGH/FGFR3, IGH/MAF, IGH/CCND3, IGH/MAFB fusion analysis in cases positive for IGH rearrangement, MYC rearrangements

 

Download PDF